Tag Archives: Merck’s

NICE rejects Merck’s Keytruda kidney cancer combo, keeping pressure off BMS

Merck’s Keytruda may be pressuring Bristol-Myers Squibb’s Opdivo in kidney cancer in the U.S. But in England, cost watchdogs won’t be giving it the chance—at least for now. The National Institute for Health and Care Excellence (NICE) shot down the combination of Merck’s star and Pfizer’s Inlyta in previously untreated patients, citing uncertainty around the combo’s… Read More »

AstraZeneca, Merck’s Lynparza lands FDA nod in tough-to-treat pancreatic cancer

Earlier this month, FDA experts voted—barely—that the agency should approve AstraZeneca and Merck’s Lynparza in pancreatic cancer. But that small majority was enough to convince regulators to follow suit. The FDA greenlighted the drug Friday as a maintenance treatment for patients with germline BRCA-mutated disease who’ve already received a round of platinum-based chemo. The approval… Read More »

FDA Approves Expanded Monotherapy Label for Merck’s Keytruda (pembrolizumab) for First-Line Treatment of NSCLC

Print this page KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded label for Keytruda, Merck’s anti-PD-1 therapy, as monotherapy for the first-line treatment of patients with stage III non-small cell lung cancer (NSCLC) who are not… Read More »